Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 5:47 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: pharmacogenetic testing Clear all
Completed No phase listed Observational

Evaluating a Pharmacogenetic Testing Panel in Patients Suspected to be at Increased Risk for Pharmacogenetics-related AEs While Receiving Fluoropyrimidine or Irinotecan Therapy

NCT05583422
View directory record Official record
Conditions
Cancer
Interventions
DPYD or UGT1A1 variants
Genetic
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 10, 2025 · Synced Sep 23, 2026, 5:47 AM EDT
Terminated Phase 1 Interventional Results available

Capecitabine and Celecoxib in Patients With Solid Cancers That Have Been Previously Treated With Standard Therapies

NCT01705106
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
capecitabine, celecoxib, pharmacological study, laboratory biomarker analysis, pharmacogenomic studies
Drug · Other
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 29, 2018 · Synced Sep 23, 2026, 5:47 AM EDT
Recruiting Not applicable Interventional

Pharmacogenomic Informed Statin Prescribing

NCT06568601
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Pharmacogenetic and polygenic risk testing, Active control
Genetic · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
40 Years to 75 Years
Enrollment
410 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Indianapolis, Indiana • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Sep 23, 2026, 5:47 AM EDT
Completed Not applicable Interventional

Clinical Study to Evaluate Patient Outcomes Following Pharmacogenetic Testing of Subjects Exhibiting Neuropsychiatric Disorders

NCT02411123
View directory record Official record
Conditions
Depression, Anxiety
Interventions
IDgenetix Neuropsychiatric Test Panel
Genetic
Lead sponsor
AltheaDx
Industry
Eligibility
18 Years to 80 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 28, 2015 · Synced Sep 23, 2026, 5:47 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Pharmacogenomics Results Affect Patients' Plan of Care and Changes in Medication Prescription(s)

NCT03322189
View directory record Official record
Conditions
Pharmacogenomic
Interventions
pharmacogenomic
Genetic
Lead sponsor
Data Collection Analysis Business Management
Other
Eligibility
18 Years to 64 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Land O' Lakes, Florida
Source: ClinicalTrials.gov public record
Updated Jan 22, 2019 · Synced Sep 23, 2026, 5:47 AM EDT
Completed Not applicable Interventional Results available

Genetically Guided Statin Therapy

NCT01894230
View directory record Official record
Conditions
Hypercholesterolemia, Hydroxy-methylglutaryl-coenzyme A (HMG Co-A) Reductase Inhibitors Adverse Reaction
Interventions
SLCO1B1*5 allele testing, results reported at randomization, SLCO1B1*5 allele testing, results reported at end of study, Genetic testing for SLCO1B1*5 allele
Genetic
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
2
States / cities
Travis Air Force Base, California • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 22, 2017 · Synced Sep 23, 2026, 5:47 AM EDT
Suspended Not applicable Interventional

The PhOCus Trial: Implementation of Pharmacogenomic Testing in Oncology Care

NCT04541381
View directory record Official record
Conditions
Gastrointestinal Cancer, Head and Neck Cancer, Dihydropyrimidine Dehydrogenase Deficiency, UGT1A1 Gene Mutation, Breast Cancer
Interventions
Availability of clinical decision support based on pharmacogenomic results.
Other
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
860 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Sep 23, 2026, 5:47 AM EDT
Completed Not applicable Interventional Results available

A Depression and Opioid Pragmatic Trial in Pharmacogenetics (Depression Trial)

NCT05966155
View directory record Official record
Conditions
Depression
Interventions
Pharmacogenetic testing, Clinical decisions support
Other
Lead sponsor
Duke University
Other
Eligibility
8 Years and older
Enrollment
1,572 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
14
States / cities
Wilmington, Delaware • Gainesville, Florida • Jacksonville, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2025 · Synced Sep 23, 2026, 5:47 AM EDT
Completed Not applicable Interventional Results available

Pilot of Preemptive Pharmacogenetics in Medically Underserved Patients

NCT04630093
View directory record Official record
Conditions
Pharmacogenetic Testing
Interventions
Panel-based pharmacogenetic genotyping
Diagnostic Test
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 99 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 3, 2023 · Synced Sep 23, 2026, 5:47 AM EDT
Terminated Phase 1 Interventional

Dabrafenib in Treating Patients With Solid Tumors and Kidney or Liver Dysfunction

NCT01907802
View directory record Official record
Conditions
BRAF Gene Mutation, Hepatic Complication, Renal Failure, Solid Neoplasm
Interventions
Dabrafenib, Laboratory Biomarker Analysis, Pharmacogenomic Study, Pharmacological Study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
17
States / cities
Duarte, California • Los Angeles, California • Sacramento, California + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2018 · Synced Sep 23, 2026, 5:47 AM EDT
Terminated Not applicable Interventional Results available

Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Measuring Effects of Pazopanib Hydrochloride in Patients With Metastatic Kidney Cancer

NCT01599832
View directory record Official record
Conditions
Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer, Stage IV Renal Cell Cancer
Interventions
pazopanib hydrochloride, laboratory biomarker analysis, dynamic contrast-enhanced magnetic resonance imaging, pharmacogenomic studies
Drug · Other · Procedure
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
4
States / cities
Chicago, Illinois • Decatur, Illinois • Harvey, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2017 · Synced Sep 23, 2026, 5:47 AM EDT
Active, not recruiting Phase 3 Interventional

Optimizing Tobacco Use Treatment for PLWHA

NCT04176172
View directory record Official record
Conditions
HIV/AIDS, Nicotine Dependence
Interventions
Varenicline, Nicotine patch, Standard treatment, Standard treatment + Managed Problem Solving (MAPS) adherence intervention
Drug · Behavioral
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
2
States / cities
Chicago, Illinois • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Sep 23, 2026, 5:47 AM EDT
Completed Not applicable Interventional Results available

Pharmacogenetic Testing Among Home Health Patients

NCT02378220
View directory record Official record
Conditions
Adverse Drug Events, Adverse Drug Reactions, Drug Interaction Potentiation, Drug Metabolism, Poor, CYP2D6-RELATED, Drug Metabolism, Poor, CYP2C19-RELATED, Cytochrome P450 Enzyme Deficiency, Cytochrome P450 CYP2D6 Enzyme Deficiency, Cytochrome P450 CYP2C9 Enzyme Deficiency, Cytochrome P450 CYP2C19 Enzyme Deficiency, Cytochrome P450 CYP3A Enzyme Deficiency, Poor Metabolizer Due to Cytochrome P450 CYP2C9 Variant, Poor Metabolizer Due to Cytochrome p450 CYP2C19 Variant, Poor Metabolizer Due to Cytochrome P450 CYP2D6 Variant
Interventions
Pharmacogenetic testing
Genetic
Lead sponsor
Genelex Corporation
Industry
Eligibility
50 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Searcy, Arkansas
Source: ClinicalTrials.gov public record
Updated Sep 19, 2019 · Synced Sep 23, 2026, 5:47 AM EDT
Completed Not applicable Interventional

Clinical Study Evaluating Effects of Pharmacogenetic-guided vs Standard-of-Care Treatment on Depression and/or Anxiety

NCT02878928
View directory record Official record
Conditions
Depression, Anxiety
Interventions
IDgenetix Neuropsychiatric Test Panel
Genetic
Lead sponsor
AltheaDx
Industry
Eligibility
18 Years and older
Enrollment
579 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
17
States / cities
Rolling Hills, California • San Diego, California • Torrance, California + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2016 · Synced Sep 23, 2026, 5:47 AM EDT
Completed Phase 4 Interventional Results available

Implementation of PPI Medication PGX Testing

NCT02794844
View directory record Official record
Conditions
Gastroesophageal Reflux
Interventions
Genotype Guided PPI Dosing
Drug
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
2 Years to 17 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Nov 20, 2018 · Synced Sep 23, 2026, 5:47 AM EDT
Completed Not applicable Interventional Results available

Prospective Genotyping For Total Hip or Knee Replacement Patients Receiving Warfarin (Coumadin)

NCT00634907
View directory record Official record
Conditions
Venous Thromboembolism, Bleeding
Interventions
Pharmacogenetic-based warfarin dosing, Usual care warfarin dosing
Genetic · Other
Lead sponsor
Gwen McMillin
Other
Eligibility
18 Years and older
Enrollment
263 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 7, 2017 · Synced Sep 23, 2026, 5:47 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Medication Therapy Management With Pharmacogenetic Testing

NCT01970774
View directory record Official record
Conditions
Pharmacogenetics, Medication Therapy Management
Interventions
MTM with PGx
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 19, 2015 · Synced Sep 23, 2026, 5:47 AM EDT
Completed Phase 1 Interventional

White Button Mushroom Extract in Preventing the Recurrence of Breast Cancer in Postmenopausal Breast Cancer Survivors

NCT00709020
View directory record Official record
Conditions
Breast Cancer, Cancer Survivor
Interventions
white button mushroom extract, flow cytometry, high performance liquid chromatography, laboratory biomarker analysis, mass spectrometry, pharmacogenomic studies, pharmacological study
Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
21 Years and older · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
2
States / cities
Duarte, California • Pasadena, California
Source: ClinicalTrials.gov public record
Updated Jun 7, 2015 · Synced Sep 23, 2026, 5:47 AM EDT
Active, not recruiting Not applicable Interventional

Effectiveness of PGx Testing

NCT04120480
View directory record Official record
Conditions
Polypharmacy
Interventions
Pharmacogenomic test
Diagnostic Test
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years to 79 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 1, 2024 · Synced Sep 23, 2026, 5:47 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Reduction of Adverse Drug Events and Readmissions

NCT02738047
View directory record Official record
Conditions
Pharmacogenomic Testing for Medication Management
Interventions
Not listed
Lead sponsor
ClinLogic LLC
Industry
Eligibility
25 Years and older
Enrollment
280,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2026
U.S. locations
1
States / cities
York, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 6, 2024 · Synced Sep 23, 2026, 5:47 AM EDT
Completed No phase listed Observational

The Clinical and Economic Impact of Pharmacogenomic Testing for Tamoxifen Metabolism in Postmenopausal Women Receiving Tamoxifen for Prevention of Recurrent Breast Cancer

NCT00830973
View directory record Official record
Conditions
Breast Neoplasms, Tamoxifen
Interventions
Poor Metabolism Status Follow Up Therapy Considerations, CYP2D6 Inhibiting Drugs
Other
Lead sponsor
Medco Health Solutions, Inc.
Industry
Eligibility
50 Years and older · Female only
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Franklin Lakes, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 13, 2009 · Synced Sep 23, 2026, 5:47 AM EDT
Completed Not applicable Interventional

Prospective Pharmacogenetic Testing and Clinical Outcomes in Patients With Early-Phase Psychosis

NCT02566057
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Psychotic Disorders, Bipolar Disorder
Interventions
PGx testing guided treatment (PGT)
Biological
Lead sponsor
Northwell Health
Other
Eligibility
15 Years to 64 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Glen Oaks, New York
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Sep 23, 2026, 5:47 AM EDT
Terminated Phase 4 Interventional

Combinatorial Pharmacogenomics Testing in Treatment-Naïve Major Depressive Disorder

NCT03537547
View directory record Official record
Conditions
Major Depressive Disorder, Depression, Depressive Disorder, Depressive Episode, Depression, Unipolar
Interventions
GeneSight Psychotropic test, FDA-approved antidepressant or antipsychotic treatment
Other · Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 4, 2020 · Synced Sep 23, 2026, 5:47 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Understand the Genetics of the Acute Response to Metformin and Glipizide in Humans

NCT01762046
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Glipizide, Metformin, Oral Glucose Tolerance Test
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 85 Years
Enrollment
1,033 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2025
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Sep 23, 2026, 5:47 AM EDT